U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Enforcement Activities | FDA
  5. Clinical Investigator Inspection List (CIIL) Database Codes
  1. Enforcement Activities | FDA

Clinical Investigator Inspection List (CIIL) Database Codes

Database Code Definitions

CIIL Search Page

The CLIIL database contains codes for Inspection Classification, Deficiency, and Type as described below.     

Classification Codes 

  • NAI - No Action Indicated.  No objectionable conditions or practices were found during the inspection. 

  • VAI - Voluntary Action Indicated.  Objectionable conditions were found but the problems do not justify further regulatory action. Any corrective action is left to the investigator to take voluntarily. 

  • OAI - Official Action Indicated. Objectionable conditions were found and regulatory and/or administrative sanctions by FDA are indicated. 

 

Deficiency Codes 

Code 

Deficiency 

Code of Federal 
Regulations (CFR) Reference 

00 

No deficiencies noted 

n/a 

01 

Records availability 

21 CFR 312.62 

02 

Failure to obtain and/or document subject consent 

21 CFR 312.60, 50.20, 50.27 

03 

Inadequate informed consent form 

21 CFR 50.25 

04 

Inadequate drug accountability 

21 CFR 312.60, 312.62 

05 

Failure to follow investigational plan 

21 CFR 312.60 

06 

Inadequate and inaccurate records 

21 CFR 312.62 

07 

Unapproved concomitant therapy 

21 CFR 312.60 

08 

Inappropriate payment to volunteers 

21 CFR 50.20 

09 

Unapproved use of drug before IND submission 

21 CFR 312.40(d) 

10 

Inappropriate delegation of authority 

21 CFR 312.7, 312.61 

11 

Inappropriate use/commercialization of IND 

21 CFR 312.7, 312.61 

12 

Failure to list additional investigators on 1572 

21 CFR 312.60 

13 

Subjects receiving simultaneous investigational drugs 

21 CFR 312.60 

14 

Failure to obtain or document IRB approval 

21 CFR 312.60, 62, 66; 56.103 

15 

Failure to notify IRB of changes, failure to submit progress reports 

21 CFR 312.66 

16 

Failure to report adverse drug reactions 

21 CFR 312.64, 312.66 

17 

Submission of false information 

21 CFR 312.70 

18 

Other 

n/a 

19* 

Failure to supervise or personally conduct the clinical investigation 

21 CFR 312.60 

20* 

Failure to protect the rights, safety, and welfare of subjects 

21 CFR 312.60 

21* 

Failure to permit FDA access to records 

21 CFR 312.68 

NG 

Not Given 

n/a 

 * Codes 19, 20, and 21 became effective October 1, 2005. 

 Inspection Type Codes 

  • DA - Data Audit: An inspection in which the focus is on verification of study data. 

  • FC - For Cause: An inspection in which the focus is on the conduct of the study by the Clinical Investigator.  

 

 

Back to Top